

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

5 June 2013

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(10 pages by email)

Dear Madam

BIOTRON TO PRESENT AT ASIA BIOTECH INVEST 2013 - HONG KONG

Biotron Limited's CEO and Managing Director Dr Michelle Miller will make a presentation this morning at the Asia Biotech Invest 2013 conference in Hong Kong.

Dr Miller will present an overview of the Company's clinical program for its first in class drug candidate BIT225, which is currently in development for the treatment of both Hepatitis C (HCV) and HIV.

Dr Miller commented: "The Company is accelerating its clinical and commercialisation activities and this conference is a timely opportunity to update our programs to a global investor audience."

A copy of the presentation is attached.

Enquiries


Dr Michelle Miller
Managing Director
Biotron Limited
+61-2 9805 0488
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn7261

BIOTRON LIMITED (ASX:BIT)

**Clinical Stage Antiviral
Drug Development Company**

Michelle Miller

CEO & Managing Director

+61 (0) 412 313 329

mmiller@biotron.com.au

Biotron



Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

Biotron Limited Overview

- Clinical stage antiviral drug development company
 - Focus on developing novel small molecule drugs
 - Clinical programs for Hepatitis C virus (HCV) and HIV
 - Earlier stage programs include Dengue and others
 - Headquartered in Sydney, Australia
- **Key recent highlights**
 - ***Mar 2013 – Announced positive preliminary headline results from Phase 2a HIV reservoir trial***
 - ***Nov 2012 – Commenced Phase 2 HIV/HCV co-infection trial***
 - ***Nov 2012 – Announced positive 48-week follow-up data from Phase 2a HCV trial***


Biotron - Advanced Pipeline of Clinical Programs

INDICATION	VIRAL TARGET	DISCOVERY	PRE-CLINICAL	PHASE 1a	PHASE 1b	PHASE 2a	PHASE 2b	STATUS
Hepatitis C	p7							<ul style="list-style-type: none"> Ph 2a complete; Ph 2b (3 mth dosing) scheduled for 4Q13
HIV	Vpu							<ul style="list-style-type: none"> Ph 2a complete
Hepatitis C/ HIV	Vpu/p7							<ul style="list-style-type: none"> Ph 2 in progress
Dengue	M							
Next generation for Hepatitis C	p7							<ul style="list-style-type: none"> Ready for IND-enabling (formal preclinical) studies

BIT225 and Hepatitis C

- New investigational oral drug for treating HCV infection
- First in class; targets p7 protein – essential for virus assembly and release
- Synergistic with IFN/RBV (current treatment) and polymerase inhibitors
- Three completed trials:
 - **Phase Ia** –Single dose, dose-escalating safety study in healthy volunteers (n=48)
 - **Phase Ib** - 7-day multiple dose study in patients with HCV (n=18)
 - **Phase 2a** – 28-day multiple dose study in patients with HCV (gen 1) in combination with IFN/RBV (n=24)
 - 12-week data presented at HepDART, Dec 2011
 - 48-week headline data presented at AASLD, Nov 2012

BIT225 HCV Phase 2 Clinical Information




Treatment	Median log reduction at 35 days	% with Early Virological Response (<50IU/ml at 12 weeks)	% with End of Treatment Virological Response (<50IU/ml at 48 weeks)
400 mg BIT225 + IFN/RBV	-4.957	86	100
200 mg BIT225 + IFN/RBV	-4.351	88	88
Placebo + IFN/RBV	-3.649	63	75


- Clear demonstration that this first in class, direct-acting antiviral drug has good antiviral activity in hard-to-treat, treatment-naïve genotype 1 patients

BIT225 and HIV

- BIT225 also has potent anti-HIV activity
 - Unique mode of action targets HIV “hiding” in long-lived reservoir cells
 - Reservoirs are last of the holy grail in HIV
 - No existing drugs target this source of HIV in the body
- Phase 2a trial of BIT225 in HIV-infected subjects recently completed
 - 10 days dosing (treatment-naïve, high viral load, CD4 >350)
- ***Headline results show that BIT225 can significantly reduce HIV levels in these reservoir cells in HIV-infected subjects***
- ***Results support a potential role for BIT225 in cure/eradication strategies***



+BIT225



Control

Biotron Opportunity

- Documented need for new antiviral drugs
 - Licensing space is very active (Gilead/Pharmasset US\$11b deal)
 - HCV worldwide market ~US\$2.8 billion; predicted to reach >US\$10 billion
- BIT225 - good clinical efficacy against both HCV and HIV
 - **Potential use with new (DAA) or existing classes of HCV drugs**
 - Phase 2b, 3 month study in combination with IFN/RBV anticipated to commence 4Q13
 - **Potential for use in HIV/HCV co-infected population**
 - Major unmet medical need
 - No other drugs target both HIV and HCV; Ph 2 trial in HIV/HCV patients in progress
 - **Potential role for BIT225 in elimination/cure strategies for HIV**
- Promising early stage drug discovery program for Dengue

Key Financials and Facts

KEY FINANCIALS		BOARD AND MANAGEMENT	
ASX Code	BIT	Mr Michael Hoy	Chairman
Recent Share Price (30 May 2013)	A\$0.10	Dr Michelle Miller	CEO & Managing Director
52 Week High	A\$0.185	Dr Denis Wade	Non-Executive Director
52 Week Low	A\$0.08	Dr Susan Pond	Non-Executive Director
Shares on Issue	228 million	Mr Robert Thomas	Non-Executive Director
Market Capitalization	A\$23 m	Mr Bruce Hundertmark	Non-Executive Director
Net Cash (31 Mar '13)	A\$5.05 m	Mr Peter Nightingale	CFO & Company Secretary



Biotron